Still in the Dark: AMD Patients Wait for Answers


Posted by Chris S on Apr 11, 2018 3:15:00 AM

In Mr. D’s sophomore English class, almost no subject was taboo or off limits. Even with our class projects, he encouraged us to pursue topics that truly interested us, and sometimes that meant having to educate Mr. D about something entirely new to him. But if your presentation included stunning visuals, you had to be prepared to paint a word picture. Macular degeneration rendered his otherwise healthy eyes all-but-useless. 

READ MORE >

Topics: Reproducibility, Neurodegeneration, Therapeutics, Immunotherapy

Webinar | Proteomics profiling of post-translational modifications in early drug discovery


Posted by Chris S on Mar 28, 2018 3:15:00 AM

Advances in mass spectrometry instrumentation and sample handling methods have propelled proteomics and extended its utility for both basic biology and early drug development. Changes in protein abundance and post-translational modification state often reflect the activity of a novel therapeutic agent as well as the sensitivity/resistance of a biological system to treatment.

READ MORE >

Topics: Proteomics, Webinars

Have You Ever Wondered...How Do I Choose a Loading Control?


Posted by Chris S on Mar 21, 2018 6:15:00 AM

For those who wish to bring a measure of rationality to the western blot data in the literature, loading controls can induce a fair amount of hand wringing. There are some obvious criteria. First, the protein level of the loading control must not be altered by experimental conditions. Second, the molecular weight of the control must be different from the protein of interest. Third, and most importantly, the signal detected for both the loading control and the protein of interest must be in a linear range, otherwise you’ll find yourself with burnt-out bands that you’ll be unable to quantify. 

READ MORE >

Topics: Western Blot

Pi Day: More Popular Than You Might Figure


Posted by Chris S on Mar 14, 2018 3:14:00 AM

It's Pi Day! 3.14! π! We've celebrated before, but this year we wanted to do something bigger. Don't get me wrong, we love baking and eating delicious pies, but have we waxed mathematical!? Well this year, CST's bravest of the brave ran our gauntlet of pi-related trivia! They didn't just eat pie, they earned it. Luckily, CST News anchor Jak Stat and the CST News team were live on the scene.

READ MORE >

Topics: Just for fun

Lifetime Achievement Award


Posted by Chris S on Feb 21, 2018 6:15:00 AM

Congratulations to our CEO and founder Dr. Michael J. Comb, whom CiteAb has selected for a lifetime achievement award. Dr. Comb likes fly-fishing in Alaska and rock climbing in Yosemite more than he likes the spotlight, but this award has given us the opportunity to acknowledge our fearless leader. CiteAb recognizes individuals from the research community for their dedication and contribution to the research reagent industry over a sustained period. Dr. Comb is being honored for his tireless efforts to build the best antibody technology in the world for researchers working to understand the molecular and cellular processes of disease.

READ MORE >

Topics: Science Education

Romantic Reagents


Posted by Chris S on Feb 14, 2018 6:15:00 AM

It’s Valentine’s Day. You can’t put out that bowl of candy hearts because…NO FOOD IN THE LAB!!! Okay, fair enough, but there has to be another way to send a message to someone special at the bench. Why not use antibodies to your advantage? The label of your vials might have all the messaging you need!

READ MORE >

Topics: Just for fun

Antibody Company of the Year (2018)


Posted by Chris S on Feb 7, 2018 6:15:00 AM

We as scientists learn from each success and failure. Sometimes it takes many failures to achieve success. And some discoveries are made with no fanfare, far from the spotlight. Other times, a good day’s work is even sweeter when you realize someone noticed!

READ MORE >

Topics: Antibody Performance, Antibody Validation, Cancer Research, Reproducility

Webinar | Achieving Reproducibility: Don't Let Antibodies Be a Variable in Your Experiment


Posted by Chris S on Jan 10, 2018 6:30:00 AM

The importance of antibodies as tools in scientific research studies cannot be understated, yet these reagents have increasingly come under fire for their lack of reproducibility. Part of the issue is that the antibody market is composed of hundreds of vendors and resellers with varying definitions for validation and consistency. Cell Signaling Technology (CST) believes that antibody suppliers should be held accountable for the products they provide, but that vendors alone cannot solve the reproducibility “crisis." How antibodies are validated and used in the laboratory is a critical component to this process. Researchers need to be more attentive to following established protocols and leverage the expertise of the scientists who have developed and tested the product they are using. Journals need to be more active in enforcing existing policies regarding materials and methods or develop more clear-cut means to identify and describe the use of biological reagents in published research. During this webinar we will address the role vendors, researchers, and journals should play in minimizing irreproducibility. We will also outline CST’s antibody validation process, while highlighting steps all users should consider when selecting and using antibodies in their research.

READ MORE >

Topics: Antibody Performance, Antibody Validation, Webinars, Reproducibility

Happy Holidays from CST!


Posted by Chris S on Dec 27, 2017 12:02:01 PM

It's hard to believe that another year is almost over. We hope you're having a lovely holiday season with you and yours. We've been fairly busy closing another quarter. But it hasn't been all business. 'Tis the season for a little nonsense to fill us all with good cheer! We couldn't think of a better way than putting on some ugly sweaters and rocking the cafeteria.

READ MORE >

Topics: Just for fun

Webinar | Validation of a Glycosylation-Independent Antibody Against the Cancer Stem Cell Marker CD133


Posted by Chris S on Nov 22, 2017 6:00:00 AM

 

ABSTRACT
The cancer stem cell hypothesis postulates that a population of self-renewing tumor-initiating cells, termed Cancer Stem Cells (CSCs), may be responsible for driving tumor heterogeneity, metastasis, therapeutic resistance and/or tumor relapse. Tools to identify and characterize putative CSCs are therefore of significant value for the cancer research community. CD133 is a 5- transmembrane (5-TM) cell surface glycoprotein that shows elevated expression in putative CSCs from multiple tumor types. Numerous studies have used antibodies directed against CD133 to isolate putative CSCs for characterization, in vitro culture, transplantation and drug discovery studies. However, the most commonly used antibodies used to study CD133+ CDCs are raised against glycosylated CD133 epitopes; this is problematic because the glycosylation status of CD133 varies in response to environmental conditions (e.g., hypoxia) or cell differentiation status. 

READ MORE >

Subscribe to Email Updates

Recent Posts